VGI Health Technology (XNEC:VTL) Price-to-Tangible-Book : (As of May. 29, 2024)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Price-to-Tangible-Book?

As of today (2024-05-29), VGI Health Technology's share price is A$0.02. VGI Health Technology's Tangible Book per Share of . 20 for the quarter that ended in . 20 was A$0.00. Hence, VGI Health Technology's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for VGI Health Technology's Price-to-Tangible-Book or its related term are showing as below:

XNEC:VTL's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.83
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, VGI Health Technology's share price is A$0.02. VGI Health Technology's Book Value per Sharefor the quarter that ended in . 20 was A$0.00. Hence, VGI Health Technology's P/B Ratio of today is .

VGI Health Technology Price-to-Tangible-Book Historical Data

The historical data trend for VGI Health Technology's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Price-to-Tangible-Book Chart

VGI Health Technology Annual Data

Trend

Price-to-Tangible-Book

VGI Health Technology Semi-Annual Data

Price-to-Tangible-Book

Competitive Comparison of VGI Health Technology's Price-to-Tangible-Book

For the Biotechnology subindustry, VGI Health Technology's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Price-to-Tangible-Book falls into.

VGI Health Technology Price-to-Tangible-Book Calculation

VGI Health Technology's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: . 20 )
	=	0.02	/
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

VGI Health Technology Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines